Ban on long-acting beta agonists for asthma

An FDA advisory panel has voted to ban the use of serevent (salmeterol) and foradil (formoteral) for the treatment of asthma, based on a comprehensive review of literature indicating that beta-agonist monotherapy for asthma is associated with higher risk of severe asthma exacerbations and possibly a higher risk of death (FDA site). For now, these agents should not be used as monotherapy for the treatment of asthma in children or adults.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment